ICF001
/ Changfeng Pharmaceutical
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 05, 2026
A Single and Multiple Dose Study to Evaluate the Safety and Effects of Inhaled ICF001 Dry Powder in Healthy Participants
(clinicaltrials.gov)
- P1 | N=72 | Not yet recruiting | Sponsor: VIVID CLINICAL SERVICES PTY LTD
New P1 trial
1 to 1
Of
1
Go to page
1